GSAE: an autoencoder with embedded gene-set nodes for genomics
  functional characterization by Chen, Hung-I Harry et al.
1	
	
GSAE: an autoencoder with embedded gene-set nodes 
for genomics functional characterization 
Hung-I Harry Chen1,2, Yu-Chiao Chiu2, Tinghe Zhang1, Songyao Zhang1,4, Yufei 
Huang1,§, Yidong Chen2,3,§ 
 
1Department of Electrical and Computer Engineering, The University of Texas at San 
Antonio, San Antonio, TX 78249, USA 
2Greehey Children’s Cancer Research Institute, The University of Texas Health Science 
Center at San Antonio, San Antonio, TX 78229, USA 
3Department of Epidemiology & Biostatistics, The University of Texas Health Science 
Center at San Antonio, San Antonio, TX 78229, USA 
4Laboratory of Information Fusion Technology of Ministry of Education, School of 
Automation, Northwestern Polytechnical University, Xi'an, Shaanxi, 710072, China 
 
§Corresponding authors 
 
Email addresses: 
YH: yufei.huang@utsa.edu 
YC: cheny8@uthscsa.edu 
  
2	
	
Abstract 
Background 
Bioinformatics tools have been developed to interpret gene expression data at the gene 
set level, and these gene set based analyses improve the biologists’ capability to discover 
functional relevance of their experiment design. While elucidating gene set individually, 
inter gene sets association is rarely taken into consideration. Deep learning, an emerging 
machine learning technique in computational biology, can be used to generate an 
unbiased combination of gene set, and to determine the biological relevance and analysis 
consistency of these combining gene sets by leveraging large genomic data sets. 
Results 
In this study, we proposed a gene superset autoencoder (GSAE), a multi-layer 
autoencoder model with the incorporation of a priori defined gene sets that retain the 
crucial biological features in the latent layer. We introduced the concept of the gene 
superset, an unbiased combination of gene sets with weights trained by the autoencoder, 
where each node in the latent layer is a superset. Trained with genomic data from TCGA 
and evaluated with their accompanying clinical parameters, we showed gene supersets’ 
ability of discriminating tumor subtypes and their prognostic capability.  We further 
demonstrated the biological relevance of the top component gene sets in the significant 
supersets.  
Conclusions 
Using autoencoder model and gene superset at its latent layer, we demonstrated that gene 
supersets retain sufficient biological information with respect to tumor subtypes and 
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clinical prognostic significance. Superset also provides high reproducibility on survival 
analysis and accurate prediction for cancer subtypes. 
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Background 
Nowadays gene set based analysis has been an essential step for interpreting gene 
expression data, for which a variety of bioinformatics tools have been developed to 
extract biological insights from different aspects. Among all methods, functional 
enrichment is the most common gene set based analysis to determine classes of genes that 
are associated with disease phenotypes, such as Gene Set Enrichment Analysis (GSEA) 
[1]. Function over-representation is another category for enrichment analysis, represented 
by The Database for Annotation, Visualization and Integrated Discovery (DAVID) [2, 3], 
among many others [4-6]. Researchers also employ gene set as a classifier; for example, 
the 50-gene PAM50 model was used to classify the subtypes of breast cancer [7]. 
Furthermore, many studies have conducted survival analysis at gene set level to predict 
clinical outcomes [8, 9]. Overall, gene set analysis improves the biologists’ capability to 
interpret functional impact to their experiment design. However, some studies have also 
disclosed the inconsistency of gene set results. Lau et al. showed that there are only 
minimal overlaps between the putative prognostic gene sets for non-small-cell lung 
cancer found in nine various studies [10]. Hence, inter gene sets association should be 
taken into consideration, as suggested by various studies, to limit inconsistency. While 
combined gene sets may provide consistency, its biological relevance are rarely 
discussed. 
    Deep learning methods have emerged recently in computational biology due to the 
increase of molecular and cellular profiling data. Convolutional neural network (CNN) 
methods were implemented for prediction of DNA-protein binding [11] or detection of 
phenotype-associated cell subsets [12]. Autoencoder, which is an unsupervised learning 
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algorithm, was used for modeling gene expression through dimensionality reduction in 
many studies [13-15]. Lin et al. proposed a supervised neural network model for single-
cell RNA-seq data that incorporate protein–protein interaction (PPI) and protein–DNA 
interaction (PDI) information. However, the prior biological knowledge was only utilized 
to improve the performance of dimensionality reduction and cell type-specific 
identification, the influence of combining PPI nodes was not examined. 
    In this study, we proposed Gene Superset AutoEncoder (GSAE), a multi-layer 
autoencoder model that incorporates a priori defined gene sets to preserve the crucial 
biological features from combining gene sets in the latent layer. We introduced the 
concept of the gene superset, an unbiased combination of gene sets, with weights trained 
by the autoencoder, where each node in the latent layer is termed a superset. The goal of 
this study is to determine the functional or clinical relevance of the learned gene supersets 
from our model, where the model evaluates gene expression data at the level of superset. 
To achieve our goal, we used large-scale RNA-seq data sets from The Cancer Genome 
Atlas (TCGA) to test GSAE and investigate the top ranked gene sets in the statistically 
significant supersets. We demonstrated that gene supersets preserve sufficient biological 
information with respect to tumor subtypes and clinical prognostic significance. Our 
study also compared different neural network classifiers and the superset classifier 
showed high accuracy in cancer subtype prediction. We concluded that superset produces 
more reproducible results than single gene sets, provides robustness in cancer subtype 
classification, and has the capability to learn potential gene sets association. 
Materials and Methods 
Data sets in this study 
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For Pan-cancer (PanCan) analysis, we collected TCGA RNA-seq data that was organized 
by TumorMap [16], which contains 9,806 samples in 33 cancer types. In addition to 
entire TCGA data, we also selected breast invasive carcinoma (BRCA) data with 1,099 
samples for characterizing network nodes. For survival analysis, lung adenocarcinoma 
(LUAD) with 515 samples were chosen. Furthermore, we used four data sets with 
sufficient survival information, LUAD, BRCA, lower grade glioma (LGG, 523 samples), 
and skin cutaneous melanoma (SKCM, 469 samples) to compare the reproducibility of 
supersets and gene sets. The expression profiles of all tumor RNA-seq in this study are in 
the Transcripts Per Million (TPM) unit and then log-transformed (logTPM = log2(TPM + 
1)), which are re-analyzed uniformly for all samples [16]. 
Gene superset autoencoder 
The architecture of GSAE is shown in Fig. 1. The input of the model is the gene 
expression profiles in log2 TPM values. The output x of the jth node in the ith layer can 
be formulated as 
 !"# = % &("()) + ,("())## !("())#   (1) 
where the bias b and the weight w are the two parameters that are learned in training, g() 
is the activation function, where we used the linear activation in the output layer and 
rectified linear unit (ReLU, defined in Eq. 2) in other layers to provide non-linearity 
while keeping a scoring feature in the model.  
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    Besides the input layer in our proposed autoencoder, the first two layers are the 
encoding network that extracts the important features from gene expression. ReLU 
activation mimics pathway activation/deactivation function, and comparing with with 
linear activation in all layers, GSAE with ReLU activation in the hidden layers has much 
better performance in cancer subtype prediction (data not shown). The decoder part 
comprises the last two layers; it is a complementary function of the encoder, and it aims 
to reconstruct the input from the converge layer. If the model is designed as a neural 
network-based classifier for cancer subtype prediction, the decoder network is replaced 
by a softmax function that is used as the output layer. At last, we choose the loss function 
to be either a mean square error function for the reconstruction loss, or a categorical 
cross-entropy function for multi-class classification error. 
Incorporate gene sets into the encoder layer 
We designed the first layer in the encoder as the gene set layer, which incorporates the 
information of a collection of gene sets. Specifically, each node in this layer represents a 
gene set, where only genes in the input layer that belong to a gene set have connection to 
the node [13], and the weight for each connection is determined by the backpropagation 
in training steps. This is different from the fully connected layer commonly used in 
autoencoder. We adopted the chemical and genetic perturbations (CGP) collection 
downloaded from the Molecular Signatures Database (MSigDB) [1, 17] and replaced 
some highly dependent gene sets with a representative gene set among them. 
8	
	
    From the output of the gene set layer, we can retrieve the gene set score of each input 
sample. Following with a dimension reduced dense layer, the superset layer (latent layer), 
can be used to investigate the combination of gene sets while keeping the crucial features 
needed to reconstruct the input data by the decoder. The superset layer is the key layer of 
our model, which we obtain a group of gene sets that correlate with divergence of cancer 
subtypes. Each node in this layer is considered as a superset, which is a combination of 
different gene set terms. In this study, we set the superset layer size to 200. With the 
information of supersets, we can analyze characteristics of the data set, such as 
development of subpopulations or clinical relevance of a disease.  
Resolve dependencies among gene sets 
The CGP collection in MSigDB includes the gene sets that represent expression 
signatures of genetic and chemical perturbations published in literature. However, some 
gene sets are highly similar, and we need to mitigate the dependency. We used a similar 
method as in our previous study [18] to cluster gene sets with significant similarity. First, 
we omitted the gene sets that have less than 15 or more than 500 genes, which is also the 
default setting in original GSEA implementation [1]. We subsequently used kappa 
statistics to measure the similarity between all gene sets. We clustered gene sets with P-
value < 10-7, and assigned the largest gene set as the representative of the cluster. At last, 
there are 2,334 CGP gene sets including 18,107 genes selected to form the gene set layer. 
Establish and train the gene superset autoencoder 
We implemented the model using Keras 1.2.2 (https://github.com/fchollet/keras) and 
used the custom layer method in Keras to accomplish the sparsity of gene set layer in 
order to keep the zero weights while optimizing the parameters. Since ReLU is used as 
9	
	
the activation function, we selected He uniform initialization as the initializers for all 
layers [19]. To train the autoencoder, we used the stochastic gradient descent (SGD) 
optimizer that was revised in Lin et al. study [13], which was designed to deal with the 
optimization problem for sparse layers. The SGD parameters were set as following, 
learning rate = 0.05, decay = 10-6, momentum = 0.9, and Nesterov = 1.  
    While training the model for a data set, we extracted 5% of data to be the validation set 
to avoid overfitting. With the callbacks.EarlyStopping() function in Keras, the model 
stops training when the loss of validation split doesn’t improve in three consecutive 
epochs. At last, we imported the data set into the trained model and exported the outputs 
and weights of the encoder layers for further analyses in R. 
The use of additional machine learning tools 
In this study, we have applied t-Distributed Stochastic Neighbor Embedding (t-SNE, 
https://cran.r-project.org/package=Rtsne) [20, 21], which has been widely used for 
dimensionality reduction. We performed t-SNE on superset results and embedded the 
high-dimensional data into a two-dimensional space, where potential subpopulations of 
the data were revealed. Another machine learning method, Hierarchical Density-Based 
Spatial Clustering of Applications with Noise (HDBSCAN, https://cran.r-
project.org/package=dbscan) [22, 23], was used in the tumor subtype analysis. 
Comparing with many other clustering algorithms, HDBSCAN has good performance 
and stability in exploratory data analysis. We performed HDBSCAN on the t-SNE results 
to determine the possible clusters among the data. Ambiguous samples were classified as 
noise and omitted from further analysis. 
Differential superset analysis between tumor subtypes 
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After performing t-SNE on the superset layer outputs, we subsequently determined the 
subtypes of a data set by using HDBSCAN. To find the supersets with a subtype pattern, 
we compared superset values between one tumor subtype (group 1) and the other 
subtypes (group 2) by one-tailed Mann-Whitney-Wilcoxon U test (MWW) with a 
location shift of “mu” (mu was assigned to change the stringency of the test). Significant 
supersets (MWW P-value < 0.01) that have larger values in group 1 were named as up-
supersets, whereas down-supersets were the significant supersets with larger than in 
group 2. We further investigated gene sets in the significant supersets. To quantify the 
contribution of ith gene set in jth superset, gsScore was calculated as following, 
 %;<=7:."# = >)(") − >@(") ×,"# (3) 
where µ1 and µ2 are the average of the ith gene set values in the two groups, and wij is the 
weight in the model corresponding to the connection from the ith gene set to the jth 
superset. In up-supersets, gene sets with gsScore greater than a positive cutoff (in the 
right tail) were selected. In the opposite, gene sets in the down-supersets with gsScore 
less than a negative cutoff (in the left tail) were selected. Those gene sets are the potential 
high impact gene sets of the subtype (group 1). 
Kaplan-Meier Survival analysis on superset layer 
To discover whether GSAE retains survival related features; for each superset and gene 
set, we used a median split (median of the superset or gene set value) to create two 
groups and performed log-rank test. For each prognostic significant superset, we ranked 
gene sets according to the gsScore (Eq. 3) and further investigated the survival relevance 
of top gene sets. 
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Results 
Cancer type information Preserved in low dimension outcome 
To test the capability of GSAE to retain crucial features in the superset layer, we used 
TCGA PanCan RNA-seq logTPM data, 15,975 genes selected with µ > 1 and σ > 0.5 
across 9,806 samples in 33 cancer types, as GSAE inputs and exported the superset layer 
results. We performed t-SNE on TCGA logTPM data and the superset layer outputs (200 
nodes), and the results are shown in Fig. 2, in which the color of each node was labelled 
according to the cancer type information. The groupings of cancer types in the two t-SNE 
plots are nearly identical, where most cancer types form an individual cluster. The 
mingling of few cancer types are also similar in both figures. We concluded that the 
model is able to retain cancer type features of a data while reducing dimensionality.  
Indication of gene sets associated with breast cancer subtypes 
In Fig.2, we learned that the samples labeled in red are separate into two clusters, and we 
further verified that they belonged to BRCA. We used GSAE to analyze the BRCA data 
separately to discover gene sets that are support this subtype differentiation. There were 
15,183 genes in 1,099 samples that meet the criterion of µ > 1 and σ > 0.5, where they 
were used as the model input. After training of the model, we exported the superset 
results and performed t-SNE, which is shown in Fig. 3A. We applied HDBSCAN, which 
clustered the samples into two groups, where group 1(G1) is labeled in red and group 2 
(G2) in green. The noisy samples defined by the algorithm were omitted. Four up-
supersets and three down-supersets were determined (P-value < 0.01) using one-tailed 
Mann Whitney U test with location shift mu = 9, where only supersets with a huge 
difference between the two groups could pass the test. In each significant superset, those 
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with gsScore > 2 sd (standard deviation of all gsScores in the superset) are the high 
impact gene sets of the superset. All high impacts gene sets of 7 significant supersets are 
listed in table S1, and the PScore (-log10(P-value)) of Mann Whitney U test (location 
shift set as 0.5) of each gene set was also included. 
    Top 15 gene sets in the most significant up-superset and down-superset are listed in 
Tables 1 and 2. The two superset density plots of gene set values (output of gene set 
nodes) in Fig. 3B and 3C show the vast difference between the two groups in those 
significant supersets. We also identified many high impact gene sets associated with 
breast cancer subtypes. For example, 
“FARMER_BREAST_CANCER_BASAL_VS_LULMINAL” clearly indicates the two 
groups are possible Basal and Luminal subtypes [24]. The study of 
“STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP” gene set also 
suggested that ESRRα might be a therapeutic target for triple negative breast cancer [25]. 
Group 1 has a higher value in “DOANE_BREAST_CANCER_ESR1_DN”, which 
matches the gene set condition where these genes were down-regulated in ESR1 positive 
samples [26]. Genes that are involved in 
“PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7” differentiates the HER2 
positive and negative BRCA subtype [27]. A study has shown that c-Myb differed 
significantly across the subtypes, where Basal-like has the lowest expression [28], which 
fits the result of “LEI_MYB_TARGETS”. There is no direct connection of Estradiol with 
breast cancer subtype, but it is an estrogen and its target gene set 
“FRASOR_RESPONSE_TO_ESTRADIOL_DN” might be a potential subtype marker. 
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    After reviewing these gene sets, because the Basal subtype accounts for 15% of the 
breast cancer population, we hypothesized that G1, the small subpopulation in red in Fig. 
3A, is the Basal subtype of breast cancer. We checked the TCGA clinical information and 
PAM50 classification results and verified that 156 of 175samples (with complete 
estrogen status or PAM50 subtype information) in G1 are either Basal-like or triple 
negative samples. This result demonstrates that our proposed superset autoencoder is able 
to reveal the subpopulation features and biological relevance. 
    We compared with GSEA results between G1 and G2, and 53 out of 124 (42.7%) high 
impact gene sets are also GSEA enriched gene sets (nom P-value < 0.05), which indicates 
the reliability of our results. To examine whether a superset contains some exclusive gene 
sets, we compared the top 3 up-supersets (Table S1A-C) and the Venn diagram is shown 
in Fig. 3D. Many of the overlapped gene sets are associated with the Basal subtype (12 
common gene sets in Table S1, bold font). Up-superset 1 has additional estrogen related 
gene sets (Table S1A, colored in blue); up-superset 2 holds some gene sets that are 
relevant to ERBB2 (Table S1B, colored in blue).  
Prediction of breast cancer PAM50 subtypes with superset classifier 
To test if our model can be used as a classifier to predict cancer subtypes, we 
reconstructed our model to the architecture shown in Fig. S1A, where the decoder 
network is replaced by a softmax function output (input – encoder – prediction output). 
With the clinical annotation organized by the UCSC Cancer Genomics Browser [29, 30] 
(captured in 2015, https://genome-cancer.ucsc.edu), we selected 821 BRCA samples with 
15,183 genes in Basal, LumA, LumB, and Her2 PAM50 subtypes as input data to test the 
performance of the superset classifier (normal-like subtype was removed due to small 
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sample size). Using 10-fold cross validation to test the superset classifier, we achieved a 
good performance of 88.79% prediction accuracy. 
    With the same input, we also compared with four different neural network models, 1) 
gene set classifier, in which the superset layer is removed (Fig. S1B), 2) 2-layer fully 
connected encoder network with the same size of the superset classifier (Fig. S1C), 3) 2-
layer fully connected encoder network, where the size of each layer was optimized by 
Hyperas [31] (Fig. S1C), and 4) 4-layer fully connected encoder network, where the size 
of each layer was optimized by Hyperas (Fig. S1D). The size and 10-fold cross validation 
accuracy of each classifier are listed in Table 3. We have tuned the SGD parameter 
setting of each model in order to get the best performance. 
    The prediction accuracy of gene set classifier (87.69%) is close to that of the superset 
classifier, which implies the gene set layer contains sufficient information for 
classification. On the other hand, all three classifiers with fully connected encoder has 
low prediction accuracy (<50%), mainly due to the large number of weights need to be 
trained to attain (or fail to attain) an optimal model. To alleviate the training burden, we 
reduced the input number by performing principal component analysis (PCA) on BRCA 
data first and selected top 500 principal components (PCs) to test the models with fully 
connected encoder (layer size was also optimized by Hyperas, Table 3). The prediction 
results (87.57%) are equivalent to the superset classifier, indicating that the gene set layer 
and top PCs both preserve important subtype features. While both PC classifier and gene 
set classifier achieved same accuracy, we can design our network to emphasize certain 
features (e.g. PAM50 subtype classification), based on the fact that we understand the 
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biological functions of a priori defined gene set, and the flexibility of choosing different 
functional sets (signaling pathways, immunological signatures, etc).   
Prognostic significance for lung adenocarcinoma 
TCGA LUAD data set was employed to test if the model is capable of retaining survival 
related features in the superset layer. With the same gene selection criterion, 15,188 
genes in 515 samples were used as the model input. We also organized the TCGA LUAD 
survival information to a 5-year survival record, where the maximum survival time was 
set as 1,825 days, and a death event that occurred after five years was counted as a 
censored event. After performing log-rank test on the superset results, we determined 6 
supersets with log-rank P-value < 0.001, which were considered as prognostic significant 
nodes. We ranked the gene sets in those six supersets by the gsScore, and the top 20 gene 
sets in each superset are listed in Table S2. The top ranked gene sets that also showed 
significance in gene set log-rank test were selected to probe the biological relevance of 
lung adenocarcinoma. 
    We picked the first and fourth ranked supersets as two examples, and the top 15 gene 
sets in the two supersets are listed in Table 4 and 5. We chose the 4th ranked superset due 
to the least overlap of significant gene sets with the 1st ranked superset. We selected three 
gene sets tested significant by the log-rank test from the two supersets and plotted the 
Kaplan-Meier survival curves in Fig. 4. In rank 1 superset, several significant gene sets 
are related to the survival of LUAD. A study has shown that decreased mRNA expression 
of TCF21, a tumor suppressor, is a core predictor for poor prognosis in patients with lung 
cancers in two studies[32-34], agree with what we found the prognosis association from 
TCGA LUAD with gene set “CUI_TCF21_TARGETS_2_UP” (P = 1.30×10-4). 
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“KIM_WT1_TARGETS_DN” (P = 0.0064) is related to the oncogene WT1 in lung 
cancer, and the high expression of WT1 links to an unfavorable impact on the prognosis 
[35]. We also found some gene sets that no previous study showed direct connection with 
the prognosis of LUAD. Previous studies have revealed that ETS-related transcription 
factors are associated with non-small-cell lung cancers (NSCLC) [36, 37]. ELK3 is also 
an ETS transcription factor, and the related gene set 
“GROSS_HYPOXIA_VIA_ELK3_UP” (P = 5.21×10-4) might be relevant to LUAD 
survival. Two chemical compounds related gene sets were discovered in superset 1, 
“MARTINEZ_RESPONSE_	TO_TRABECTEDIN_DN” (P = 0.0015) and 
“CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN” (P = 0.0264). While both 
gene lists were derived from studies of other cancer types (e.g., HCT116 colon cancer 
cell-line), other studies has demonstrated the effectiveness of both Epoxomicin and 
Trabectedin in lung cancer treatment. Carfilzomib, which is a designed drug based on 
Epoxomicin, demonstrated anti-proliferative activity and resulted in prolonged survival in 
mice with SHP-77 small cell lung cancer xenografts [38]. There was only one study 
testing treatment with trabectedin on NSCLC patients, but no recommendation was given 
to use trabectedin as single agent treatment [39]. Thus, these two gene sets could be 
further examined to look for the biological relevance to LUAD. 
    In 4th ranked superset, “IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP” 
(P = 0.0249) is a widely studied gene set to show the association with LUAD prognosis. 
The study that concluded this gene set observed the aberration in NSCLC with oncogenic 
form of KRAS and inactivated PTEN, in which condition resulted shorter survival [40]. 
The gene set “ZHANG_BREAST_CANCER_PROGENITORS_UP” (P = 0.0248) shows 
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the effect of progenitor cells in survival. Ooi et al. suggested that the presence of a 
putative tumor-initiating progenitor cell population in NSCLC is a biomarker with a 
worse prognosis [41]. MAPK8 related gene set 
“YOSHIMURA_MAPK8_TARGETS_DN" (P = 0.0195) is also a potential prognostic 
associated gene set, while only one study implied indirect impact of poor prognosis due 
to MAPK8 repression [42]. 
    From the two selected supersets, we already found some gene sets highly associated 
with LUAD survival, there are some novel prognostic gene set candidates that need to be 
further studied. In conclusion, superset results encompass survival-associated features 
and sort out the priority of potential prognostic gene sets. 
Improved survival reproducibility from supersets 
To compare the reproducibility of survival results between the superset and gene set 
layers, we selected four TCGA data sets (BRCA, LUAD, SKCM, and LGG) to examine 
the reproducibility of GSAE. For each data set, we omitted genes that did not meet the 
criterion of µ > 1 and σ > 0.5. We next randomly split 60% of the data as the training set 
and the remaining 40% as the test set. After the autoencoder was trained on the training 
set, we obtained the superset outputs for the training and test sets. Median split and log-
rank test were performed on training and test superset results to determine survival-
related supersets and gene sets. 
    We assumed that the prognostic significant gene sets and supersets should be similar 
between training and test data. To evaluate the performance of gene set and superset 
results, we compared the significant gene sets and supersets obtained from training data 
and those from test data by Jaccard index. Furthermore, we used two population 
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proportions z-test to examine whether supersets have greater overlap proportion in the 
training data, and the results are shown in Table 6. 
    In the largest data set BRCA, we found out that superset has much higher Jaccard 
index (34%) than gene set (12%), and the two overlap proportions differ significantly (P 
= 2×10-4). In two other smaller data sets, LUAD and SKCM, superset (Jaccard Index 
~18%) still outperforms gene set (11% and 7% for LUAD and SKCM, respectively; z-
test P-value < 0.05). In LGG, because of the large number of prognostic significant nodes 
for superset and gene sets, both Jaccard coefficients are high (~48% for both superset and 
gene set) and the performance of gene set and superset is identical. To avoid the potential 
of sampling bias, we repeated the whole process in BRCA and LUAD several times, and 
we obtained similar stability measure (z-test P-value, data not shown). Overall, we 
concluded that superset has better reproducibility performance over gene set. 
Discussion 
Same as other machine learning algorithms, the selective process of GSAE is an issue. 
Despite getting identical losses, different nodes (or gene sets) in different training may 
selective activated or de-activated (output value ~0) with the same training data. Take our 
study for example, we might obtain the same outcome (e.g. tumor subtype classification) 
of a dataset in the superset layer, but it is difficult to match superset between runs, and 
the top ranked gene set components in significant supersets might also be different, 
although highly relevant gene sets appear more frequent. This observation can be used to 
assess the significance of a given gene set or superset to a specific aim (e.g. survival 
association).  
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    We also tried to understand the major cause of selective process in our model, and two 
possible factors were concluded – the dependency among gene sets in the CGP collection 
and the initialization of the model weights. Even though we tried to mitigate the 
dependency effect, many gene sets still share a subset of genes. In the model, we 
observed that some gene sets with zero values (deactivated) are highly overlapped with 
top ranked gene sets (activated). We assume that the information (member genes) of a 
zero-value gene set can be replaced by a combination of other gene sets. In addition, all 
weights in the GSAE model are randomly initialized. Due to the randomly initialized 
weights and dependency among gene sets, the model can reconstruct the input data 
through different gene sets, which results in the selective process of activated or 
deactivated gene sets. A better choice for independent or less overlapping gene sets could 
be Gene Ontology (GO) slims, a cut-down version of the whole GO. We might also 
alleviate this selective issue by assigning saved initial weights from a previous run or pre-
trained weights of other data.  
    Another limitation of our model is the requirement of large sample size, which is a 
constraint for usual bulk RNA-seq experiments. However, the characteristic of single-cell 
RNA-seq (scRNA-seq) experiments, lower read depth with much larger sample size (near 
half-million scRNA-seq in some studies [43, 44]), perhaps is more suitable to be 
analyzed by deep learning methods. There are many advantages to examine scRNA-seq 
data using GSAE. First, scRNA-seq analysis with our model will not be restricted by 
statistical assumptions, where we can avoid dealing with the diverse statistical 
characteristics of single-cell data [45]. Second, we can directly determine the exclusive 
gene sets or GO functions of each identified subpopulation, without the need to find the 
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representative genes of a subpopulation. With the support of other additional tools, 
analyzing scRNA-seq data with our model will be more thorough. For example, using 
only highly variable genes detected by scVEGs [46] will increase the diversity of 
subpopulations while lowering the variable dimension of the model. The HDBSCAN 
algorithm can cluster the multiple subpopulations of single-cell data precisely after t-SNE 
is applied. Overall, there is a huge potential using deep learning methods for scRNA-seq 
data analysis. 
    The concept of gene supersets not only provides better reproducibility, it also gives us 
a chance to understand the inter-dependency of gene sets. In this study we investigated 
the associations between significant supersets and gene sets. However, relations between 
those top ranked gene sets in the same superset has yet to be discussed. One possible 
solution is to find the corresponding input genes that have large contribution to a 
significant superset (by interpreting the weights in the first layer as the gene weights in 
each gene set), where we can further form a set of genes based on the superset. All these 
alternative approaches will guide our future study to bolster the biological functions of 
supersets. 
Conclusions 
In this paper, we proposed a multi-layer autoencoder model with the incorporation of 
annotated gene set information. The model is capable of preserving crucial biological 
features of gene expression data in the dimension reduced superset layer. From the 
superset results, we have found out information such as tumor subtype differentiation and 
clinical prognostic significance. With the concept of superset, an unbiased combination 
of gene sets, we can improve the reproducibility of survival analysis, provide robust 
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prediction of cancer subtypes, and indicate potential gene sets association of a disease. 
GSAE has the versatility to incorporate different gene set collection, discover different 
biological relevance, and analyze different kinds of gene expression data. 
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Figures Legends 
Figure 1. The architecture of gene superset autoencoder (GSAE). In the gene set layer, 
one color node represents a gene set, and edges in the same color show connect associate 
genes to a gene set. 
Figure 2. The t-SNE results of TCGA 9,806 samples using (A) logTPM data with 15,975 
genes (an initial PCA step was performed), and (B) 200 superset outputs.  
Figure 3. Subtype analysis in BRCA data set. (A) The t-SNE results of BRCA data, 
where HDBSCAN classified the samples into two groups. The noisy samples were 
labeled in black and omitted from further analysis. (B) The density plots of the most 
significant up-superset and three selected top gene sets. The blue/yellow arrow 
corresponds to positive/negative weight in the model between the gene set and superset. 
(C) The density plots of the most significant down-superset and three selected top gene 
sets. (D) The Venn diagram of the significant gene sets in the top 3 up-supersets. 
Figure 4. The Kaplan-Meier Curves of (A) 1st ranked superset and selected three top 20 
gene sets associated with the superset (B) 4th ranked superset and selected three top 20 
gene sets associated with the superset. The blue/yellow arrow corresponds to 
positive/negative weight in the model between the gene set and superset. 
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Tables 
Table 1.	Top 15 gene sets in up-superset #1 in BRCA subtype analysis. 
Gene Set Terms PScoreA gsScore weightB 
CUI_TCF21_TARGETS_2_UP 81.999 0.980 0.198 
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7 92.578 0.927 -0.154 
GRADE_COLON_AND_RECTAL_CANCER_UP 68.314 0.427 0.138 
DOANE_BREAST_CANCER_ESR1_DN 87.537 0.374 0.066 
VANTVEER_BREAST_CANCER_ESR1_DN 80.186 0.366 0.083 
HATADA_METHYLATED_IN_LUNG_CANCER_UP 76.111 0.333 -0.103 
FARMER_BREAST_CANCER_BASAL_VS_LULMINAL 90.606 0.321 0.079 
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_ 
MODERATELY_UP 
80.636 0.247 -0.113 
BOQUEST_STEM_CELL_DN 10.658 0.245 -0.130 
BONOME_OVARIAN_CANCER_SURVIVAL_OPTIMAL_ 
DEBULKING 
54.414 0.228 -0.100 
MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP 88.073 0.206 -0.059 
YANG_BREAST_CANCER_ESR1_DN 71.886 0.194 0.088 
DOUGLAS_BMI1_TARGETS_DN 18.273 0.177 -0.127 
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ 
ESTROGEN_UP 
84.141 0.174 -0.076 
BERNARD_PPAPDC1B_TARGETS_DN 88.410 0.161 -0.073 
AThe PScore of gene set Mann Whitney U test with location shift = 0.5.  
BThe weight in the model corresponding to the connection of a gene set to the corresponding superset.  
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Table 2.	Top 15 gene sets in down-superset #1 in BRCA subtype analysis. 
Gene Set Terms PScoreA gsScore weightB 
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7 92.578 0.997 0.166 
VANTVEER_BREAST_CANCER_ESR1_DN 80.186 0.811 -0.185 
LEI_MYB_TARGETS 55.903 0.800 0.201 
DOANE_BREAST_CANCER_ESR1_DN 87.537 0.644 -0.114 
CUI_TCF21_TARGETS_2_UP 81.999 0.511 -0.103 
ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_ 
TUMOR_DN 
46.415 0.340 0.127 
DELACROIX_RARG_BOUND_MEF 55.442 0.336 0.141 
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_UP 37.512 0.230 -0.074 
FRASOR_RESPONSE_TO_ESTRADIOL_DN 77.02 0.218 0.108 
HATADA_METHYLATED_IN_LUNG_CANCER_UP 76.111 0.215 0.066 
SMID_BREAST_CANCER_LUMINAL_A_UP 51.385 0.211 0.077 
FOSTER_KDM1A_TARGETS_UP 62.021 0.188 0.091 
SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12 6.764 0.178 -0.096 
SWEET_LUNG_CANCER_KRAS_UP 6.548 0.178 0.138 
KOYAMA_SEMA3B_TARGETS_DN 24.534 0.176 0.094 
AThe PScore of gene set Mann Whitney U test.  
BThe weight in the model corresponding to the connection of a gene set to the superset.  
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Table 3.	The size of encoder layers and the 10-fold cross validation accuracy of each 
neural network classifier.  
NN 
classifier A 
Input 
Type 
Encoder 
Layer  
1D 
Encoder 
Layer  
2 
Encoder 
Layer  
3 
Encoder 
Layer  
4 
Accuracy of  
10-fold cross 
validation 
Superset GenesB 2,337 200   88.79% 
Gene set Genes 2,337    87.69% 
2-layer fc Genes 2,337 200   47.86% 
2-layer fc Genes 2,000 500   37.98% 
4-layer fc Genes 2,000 200 100 50 46.06% 
2-layer fc PCC 400 100   87.57% 
4-layer fc PC 200 200 100 25 87.57% 
A2-, 4-layer fc: 2- or 4- layer fully connected AE.  
BGenes input is the 15,183 genes of TCGA BRCA RNA-seq data.  
CPC Input is the top 500 principal components of PCA analysis.  
DThe encoder layer 1 of superset and gene set classifier is the gene set layer (not a fully connected layer).  
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Table 4.	Top 15 gene sets in the highest ranked superset in LUAD survival analysis. 
Gene Set Terms P-valueA gsScore weightB 
CUI_TCF21_TARGETS_2_UP 1.30×10-4 0.446 -0.211 
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS 
_POORLY_DN 
2.02×10-4 0.254 -0.201 
GROSS_HYPOXIA_VIA_ELK3_UP 5.21×10-4 0.245 0.115 
KAAB_HEART_ATRIUM_VS_VENTRICLE_DN 5.10×10-4 0.194 0.145 
MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN 0.0015 0.183 0.107 
MITSIADES_RESPONSE_TO_APLIDIN_UP 0.2863 0.159 -0.171 
KIM_WT1_TARGETS_DN 0.0064 0.146 0.081 
ENK_UV_RESPONSE_EPIDERMIS_UP 1×10-5 0.143 0.077 
SENESE_HDAC1_TARGETS_DN 0.8285 0.138 -0.162 
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH 
_LMP1_UP 
0.1411 0.129 -0.130 
YANG_BCL3_TARGETS_UP 0.0299 0.126 0.163 
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN 0.9507 0.124 0.132 
CONCANNON_APOPTOSIS_BY_EPOXOMICIN_DN 0.0264 0.112 0.147 
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP 0.0048 0.110 -0.051 
RHEIN_ALL_GLUCOCORTICOID_THERAPY_DN 0.0154 0.107 0.051 
AThe P-value of gene set log-rank.  
BThe weight in the model corresponding to the connection of a gene set to the superset.  
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Table 5.	Top 15 gene sets in 4th ranked superset in LUAD survival analysis. 
Gene Set Terms P-valueA gsScore weightB 
SWEET_LUNG_CANCER_KRAS_DN 0.7304 0.780 -0.185 
ZHANG_BREAST_CANCER_PROGENITORS_UP 0.0248 0.256 0.096 
ROZANOV_MMP14_TARGETS_UP 0.1038 0.161 0.103 
MONNIER_POSTRADIATION_TUMOR_ESCAPE_DN 0.0058 0.157 -0.117 
ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER 
_MODEL_DN 
0.0988 0.154 0.114 
YOSHIMURA_MAPK8_TARGETS_DN 0.0195 0.150 -0.126 
DELYS_THYROID_CANCER_DN 0.0065 0.125 -0.079 
SWEET_LUNG_CANCER_KRAS_UP 0.2762 0.122 0.141 
OSWALD_HEMATOPOIETIC_STEM_CELL_IN_COLLAGEN
_GEL_DN 
0.0132 0.101 0.120 
GROSS_HYPOXIA_VIA_ELK3_UP 5.21×10-4 0.100 0.058 
WATTEL_AUTONOMOUS_THYROID_ADENOMA_UP 0.1555 0.096 -0.089 
VERHAAK_GLIOBLASTOMA_MESENCHYMAL 0.7314 0.095 0.113 
PHONG_TNF_RESPONSE_NOT_VIA_P38 0.0972 0.093 -0.121 
RUTELLA_RESPONSE_TO_HGF_UP 0.7217 0.091 -0.055 
IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP 0.0249 0.090 0.088 
AThe P-value of gene set log-rank.  
BThe weight in the model corresponding to the connection of a gene set to the superset.  
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Table 6.	The statistical information of GSAE outputs between the training and test 
TCGA data sets of four cancer types.  
   Two proportion z-test 
 
TCGA  
data set 
Superset 
Jaccard 
IndexA 
Gene set 
Jaccard 
IndexB 
Superset 
ProportionC 
Gene set 
ProportionD 
 
P-valueE 
BRCA 34.38% 12.35% 11 / 24 31 / 197 0.0002 
LUAD 18.18% 11.27% 6 / 12 32 / 145 0.0150 
SKCM 17.86% 6.88% 5 / 19 17 / 139 0.0485 
LGG 48.33% 47.54% 29 / 45 299 / 481 0.3821 
Supersets/gene sets with log-rank P-value < 0.05 were selected as prognostic significant sets.  
AJaccard index of significant supersets between training and test data.  
BJaccard index of significant gene sets between training and test data.  
CSuperset proportion: (# of overlapped significant supersets between training and test data) over (# of 
significant supersets in training data).  
DGene set proportion: (# of overlapped significant gene sets between training and test data) over (# of 
significant gene sets in training data).  
EThe P-value of z-test comparing superset and gene set proportions.  
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Additional files 
Additional file 1 – Fig_S1.pdf 
The architectures of four neural network classifiers. (A) superset classifier, (B) gene set 
classifier, (C) 2-layer fully connected encoder network classifier, and (D) 4-layer fully 
connected encoder classifier. 
Additional file 2 – Table_S1.xlsx 
Top high impact gene sets of the four up-supersets and three down-supersets in the 
BRCA tumor subtype analysis. The highly overlapped collections of a gene set were 
determined by MSigDB (in the compute overlaps section). 
Additional file 3 – Table_S2.xlsx 
Top 20 gene sets of the six prognostic significant supersets in LUAD survival analysis. 
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